Protein-engineered bypassing agents have the potential to treat bleedi – McqOptions

MCQOPTIONS

1.	Protein-engineered bypassing agents have the potential to treat bleeding in haemophilia patients with inhibitors.
A.	False
B.	True
Answer» C.

Discussion

No Comment Found

Related MCQs

APC inactivates FVIIIa by proteolytic cleavage at which of the following sites?
How many alternatively spliced transcripts are produced by factor VIII gene?
The potency of gene therapy vectors can be enhanced by using bioengineered extended half-life (EHL) FVIII or FIX fusion proteins as transgenes.
Removing which of the following enzyme cleavage site impedes the A2 dissociation?
Small changes in the amino acid sequence of proteins can have a profound effect on their immunogenicity.
Which of the following can inactivate the activated FVIII?
Furin Cleavage is necessary for FVIII biological functions.
Which of the following enzyme cleaves fibrinogen into fibrin which polymerizes and crosslinks (using factor VIII) into a blood clot?
Which of the following factors require LMAN1-facilitated transport from the ER to the Golgi?
Protein-engineered bypassing agents have the potential to treat bleeding in haemophilia patients with inhibitors.